A pharmacist's guide to the 2012 update of the Canadian Cardiovascular Society Guidelines for the Use of Antiplatelet Therapy

摘要

The initial Canadian Cardiovascular Society (CCS) Guidelines on the Use of Antiplatelet Therapy1 covered chronic antiplatelet therapy for a number of diseases and patient subgroups. The 2012 Focused Update2 specifically addressed the issues of antiplatelet therapy for secondary prevention in the first year after acute coronary syndrome (ACS), percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG) and the interaction between clopidogrel and proton pump inhibitors (PPIs). The updating of these topics and the prominence of the newer antiplatelet agents in the guidelines make them of particular relevance to pharmacists. The intent of this publication is to highlight components of the guidelines that are most likely to affect the practice of pharmacists and provide practical information to assist pharmacists in managing patients on antiplatelet therapy.